Metabolic Health
The GLP-1 Pipeline: Triple Agonists, Older Adults, and the Cautious Move Toward Type 1
A wave of 2025 reviews and trial analyses sketches what comes after tirzepatide — broader populations, bigger weight-loss numbers, and tentative steps into autoimmune diabetes.